Polling
    
                
    
        
                
                                        
                     
                    
                    
                    
                    
                
Pharmaceutical ads
                                                                                                    
For decades, the pharmaceutical industry has claimed that research costs are the reason American drugs are so expensive compared to the rest of the world. However, facts show that many of these firms spend more on advertising than on research, some more than twice as much. For several years now, Americans have been bombarded with TV ads for prescription medications. In 2024, pharmaceutical manufacturers spent more than $10 billion on direct-to-consumer television, radio, online, magazine and newspaper advertising. Drug makers now market their products directly to consumers, rather than the traditional method of allowing doctors to make treatment recommendations. Pharmaceutical companies often air ads for products that treat sexual dysfunction, incontinence, pain, hormone imbalance or depression -followed by lengthy warnings of possible horrific side-effects from using their products. Some critics claim these types of ads are not appropriate to be viewed by children. They also say drug ads are not produced by people who are experts in healthcare, but who are somewhat competent in sales and marketing. Advocates say these ads should be considered for what they are, a promotion, not a source of factual consumer information. They claim most consumers are not adequately informed to assess the accuracy or truth of a drug ad, or whether it is appropriate for their condition, or if they even have a condition that requires such medication. 
Pending Legislation: H.R.1117 - Responsibility in Drug Advertising Act of 2025
Sponsor: Rep. Rosa DeLauro (CT)
Status: House Committee on Energy and Commerce
Chair: Rep. Brett Guthrie (KY)
Pending Legislation: H.R.1117 - Responsibility in Drug Advertising Act of 2025
Sponsor: Rep. Rosa DeLauro (CT)
Status: House Committee on Energy and Commerce
Chair: Rep. Brett Guthrie (KY)
Suggestion
                    
                            Poll Opening Date
        November 3, 2025
    Poll Closing Date
        November 9, 2025